Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia

Critical Care Medicine

Volumn 28, Issue 8, 2000, Pages 2881-2886

  Pulletz, Sven ^a   Lehmann, Christian ^a   Volk, Thomas ^a   Schmutzler, Martin ^a   Ziemer, Sabine ^b   Kox, Wolfgang J ^a   Scherer, Ralf U ^c,d  

^a Klinik fur Anasthesiologie und Operative Intensivmedizin   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Klinikum Duisburg   (Germany)

^d Evangelisches/Johanniter Klinikum   (Germany)

Author keywords

Antithrombin; Coagulation; Endothelium; Endotoxin; Heparin; Hirudin; Intravital microscopy; Pr ostacyclin; Rat; Thrombin

Indexed keywords

ANTITHROMBIN; ENDOTOXIN; FIBRINOGEN; HEPARIN; HIRUDIN; LEPIRUDIN; LIPOPOLYSACCHARIDE; PROSTACYCLIN; SODIUM CHLORIDE; THROMBIN ANTITHROMBIN COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; FIBRINOGEN BLOOD LEVEL; IN VIVO STUDY; MALE; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; RAT;

EID: 0033842899     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200008000-00032     Document Type: Article

References (21)

1. Human antithrombin concentrates and experimental disseminated intravascular coagulation
2. Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat
3. Protective effect of antithrombin III in acute experimental pancreatitis in rats
4. Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction
5. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomized, multicenter study
6. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure
7. Anticoagulantly active heparan sulfate proteoglycan and the vascular endothelium
8. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells
9. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells
10. Effects of antithrombin III (AT III) and Trp49-modified AT III on plasma level of 6-keto-PGF1 alpha in rats
11. Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: Novel biological activity of AT III
12. Inhibition of tumor necrosis factor-α release in rat experimental endotoxemia by treatment with the 21-aminosteroid U-74389G
13. Reduction of mortality with antithrombin III in septicemic rats: A study of Klebsiella pneumoniae induced sepsis
14. Short-time rabbit model of endotoxin-induced hypercoagulability
15. Chemical stability of prostacyclin (PGI2) in aqueous solutions
16. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion
17. Antithrombin III (ATIII) prevents increased permeability and leukocyte adhesion in the microcirculation of rat mesentery in response to endotoxin
18. The anti-inflammatory properties of antithrombin III: New therapeutic implications
19. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin
20. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats
21. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III